Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Addex Therapeutics ( (CH:ADXN) ) is now available.
Addex Therapeutics reported significant progress in its drug development programs and business milestones for the first half of 2025. The company demonstrated robust anti-tussive activity in its GABAB PAM chronic cough candidate, regained rights to its phase 2 mGlu2 PAM asset, and entered an option agreement with Sinntaxis for mGlu5 NAM in brain injury recovery. Additionally, Addex invested in Stalicla, underscoring its commitment to innovative CNS disorder treatments. Financially, Addex experienced a decrease in income and cash position, with a net loss increase due to discontinued operations and investment losses.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel small molecule allosteric modulators for neurological disorders. The company is advancing its lead drug candidate, dipraglurant, for brain injury recovery and has a partnership with Indivior for a GABAB PAM drug candidate targeting substance use disorders. Addex is also progressing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing various allosteric modulator programs.
Average Trading Volume: 452,905
Current Market Cap: CHF11.98M
For a thorough assessment of ADXN stock, go to TipRanks’ Stock Analysis page.